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CASE REPORT 
Intravenous Valproate Therapy 
NILESH SHAH, SUJIT SHENOY, PRADNYA GAWDE 
ABSTRACT 
Four cases of acute manic episode (bipolar-l disorder), not responding to oral 
valproate or other mood stabilizer and neuroleptics were given injection valproate 
intravenously. Three out of 4 patients showed good response and tolerance to 
intravenous valporate. 
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INTRODUCTION 
Valptoare has emerged as an efficacious 
medication in the management of acute 
manic episode and in the long-term main-
tenance therapy of bipolar mood disorder 
(Bowden et al., 1994; McElroy et al., 1996). 
Injection valproate is now available for 
intravenous use. When valproare is admin-
istered intravenously; the peak plasma 
concentration is reached faster, the hepatic 
first-pass metabolism is bypassed and the 
gastrointestinal disturbances are less com-
mon (Devisky et al., 1995). Duggal et al, 
(2000) found intravenous valproate to be 
efficaceous in a case of schizoaffective 
disorder. 
The report summaries the use of in-
jection valptoate administered intravenously 
in 4 cases of acute manic episode (bipolar-
I disorder) (APA, 1994). 
The following protocol (Grunze er al., 
1999) was used in all the 4 patients for 
administration of intravenous valproate. 
Dosage of the drug was decided empirically 
as per the following protocol and it was not 
based on the body weight of the patients. 
Each ml of injection valproate contains 
100 mg of valproic acid. At a time 250 mg 
of injection valproare (2.5 ml) diluted in 250 
ml of normal saline was given to the patient 
in the form of slow infusion drip over a 
period of 1 hour. 
combination of valproate and clozapine. 
She was hospitalised and started on 
intravenous valporate as per the protocol 
mentioned above. Oral valproate was stopped 
and clozapine 200 mg/day continued. 
After the 1st infusion on day-1, on 
clinical assessment some improvement was 
observed in the patient's behaviour. On day 
5 relatives reported that her manic symptoms 
had reduced subtantially. By day 15 patients 
was in complete remission. At present she 
is maintained on 750 mg of oral valproate 
and 200 mg of clozapine. 
CASE REPORT - 2 
A 17 year old female patient, suffering 
from bipolar-I disorder since 18 months 
) 
Davs  Form  Dose  Frequency 
Day 1, 2, 3 
Day 4, 5, 6 
Day 7 onwatd 
Day 15 onward 
Inj. valproare 
Inj. valproate 
lnj. valproate 
Tab, valproate 
250 mg TV 
250 mg IV 
250 mg IV 
250 mg tirally 
Once daily 
Twice dady 
Thrice daily 
Thrice daily 
Injection Valproate was continued Day-7 onwards till the remission was achieved. 
Valproate was started from the day of remission or Day-15 onwards. 
Blood pressure of die patients was monitored 
twice everyday during hospitalization, keeping 
in view the side effect of hypotension due 
to intravenous Valproate. Patients were also 
monitored for development of 
hypersensitivity to the drug. 
CASE REPORT - I 
A 50 year old female patient, suffering 
from bipolar-I rhiorder since 20 years, 
maintained on lithium, presented with acute 
manic episode and symptoms of 
hypothyroidism low pulse rate, odema face 
and feet. So lithium was stopped and she 
was started on carbamezapine. As she did 
not tolerate earbamazepine, she was switched 
to oral valproate, which was gradually in-
creased to 1750 mg per day over a period 
or 3 weeks. Clozapine 200 mg per day was 
added, since no significant improvement 
was noted with valproate alone. When she 
did not show any improvement widi the 
presented with acute manic episode. As she 
did not respond to a course of lithium and 
halopetidol combination over a period of 
2 weeks) she was administered a course ot 
8 ECTs. Since this also was not very useful, 
tablet clozapine 200 mg per day was added. 
With this a substantial clinical improvement 
was observed. But on follow up visit, she 
complained of excessive sedation and in-
continence of urine during sleep. Clozapine 
had to be reduced and stopped. But after 
stopping clozapine manic symptoms in-
creased and so the patient was started on 
intravenous valproate as per the protocol 
mentioned above, in this patient also, after 
the 1st infusion on day-1, clinical assessment 
showed some improvement in patient's 
behavior. On day-5 a significant improve-
ment in grandiosity was noted. By day- 15 
she was in complete remission. During the 
therapy she complained of nausea and had 
one episode of vomiting. At present she is 
well maintained only on 750 mg of oral 
valproare. 
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CASE REPORT-3 
A 52 year old male patient, suffering 
from bipolar-I disorder since 25 years, had 
6 episodes of mania in 2001 and so was 
considered as rapid cyeler. He was tried on 
various combinations of lithium, clozapine, 
olanzapine, lorazepam, thioridazine and had 
received a course of 10 ECTs with little 
improvement. So he was considered for 
intravenous valproate fherapy. 
Like previous 2 patients, this patient also 
showed a substantial improvement in 
psychomotor agitation after the 1st infusion 
of valproate on day-1. By the 5th day a very 
significant improvement was observed 
clinically and almost complete remission 
was achieved by the day-9. At present 
patient is well maintained on 800 mg or oral 
valproate. This patient did not have any 
side-effects except minimal sedation. 
CASE REPORT-4 
A 16 year old female patient, suffering from 
bipolar-I disorder since 1 year was brought 
by her relatives with acute manic episode. 
She was treated with haloperidol, 
chlorpromazine, carbamazepine, 
oxcarbazepine, and a course of 6 ECTs over 
a period of 4 weeks. She had developed 
ataxia with carbamezapine and diplopia with 
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oxcarbazepine. As she did not show any 
substantial improvement clinically and had 
adverse reactions to the mood stabilisers, 
she was considered for intravenous valproate 
therapy. 
Unlike the previous 3 patients, in this 
patient, no improvement in symptoms was 
observed after the infusion on day-1 and 
even on day-5 there was only a minimal 
improvement. On day-6 Patient developed 
giddiness, ataxia and incoordination and so 
the therapy was discontinued. 
DISCUSSION 
Intravenous valproate therapy for acute 
manic episode seems to be a very useful 
option. Though there are no formal guide-
lines or criteria, developed for the use of 
intravenous vaiproate, One may prefer to 
use it for die patients who do not respond 
to oral valproate, or otiier mood stabilizers 
and antipsychotic medications. The onset of 
improvement is almost immediate and a 
substantial improvement is noticed within 5 
days of the treatment. Most of die patients 
seem to tolerate this therapy well, diough 
some of them may have excessive sedation, 
nausea, vomitting or CNS side effects. 
While using this therapy, one needs to be 
careful as patients may develop hypotension 
or hypersenstrvity reaction. The positive 
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clinical experience warrants a double-blind 
placebo controlled trial to confirm diese 
findings. 
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